This announcement is a separate document:
北京市通商律师事务所关于华熙生物调整 2021年限制性股激励计划首次及预授价格、作废部分已授予尚未归属的限制性股票及首次授予部分第二个归属期及预留授予部分第一个归属期归属条件成就事项之法律意见书
Legal opinion of Beijing Trade Law Firm on Huaxi Biotech's adjustment of the initial and pre-order prices of the 2021 restricted stock incentive plan, the annulment portion of restricted shares that have not yet been granted, and the first grant of part of
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.